Mandate

Vinge advises Schwarz Group on the market entry of its environmental division PreZero in Sweden in connection with PreZero's acquisition of SUEZ’s waste management and recycling operations in Sweden.

SUEZ has more 50 recycling sites and around 1,000 employees in Sweden.

The transaction is subject to antitrust clearance and closing of the transaction is expected at the end of 2020.

Vinge's team consisted of Matthias Pannier, Ulrich Ziche, Linda Sengul and Jesper Lindvall together with Nina Gransäter (M&A), Mathilda Persson, Jolene Reimerson, Mika Jordan, Ellinor Wargenbrant, Christoffer Nordin, Lisa Hörnqvist, Marion Kronberg and Hayaat Ibrahim (IT & Commercial Agreements), Johan Cederblad and Olof Löfvenberg (Environmental & permits), Sara Strandberg and Veronika Garemark (Employment), Jack Bengtsson and Martin Svanberg (Financing), Sofia Bergenstråhle (IP), Kristoffer Larson (Real Estate), Maria Schultzberg (Tax), Nathalie Hughes and Carl Bruneheim (VDR assistants) as well as Jasmina Skandrani (Project assistant).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026